Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Akebia Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AKBA
Nasdaq
2834
https://akebia.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Akebia Therapeutics Inc
Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference
- May 19th, 2022 12:30 pm
Why Are Akebia Therapeutics Shares Falling Today?
- May 16th, 2022 6:13 pm
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates
- May 9th, 2022 10:25 pm
Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update
- May 9th, 2022 8:05 pm
Zoetis (ZTS) Tops Q1 Earnings and Revenue Estimates
- May 5th, 2022 12:25 pm
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?
- May 2nd, 2022 7:00 pm
Akebia Therapeutics to Report First Quarter Financial Results
- May 2nd, 2022 12:30 pm
Following FDA rejection, Akebia lays off 180 workers
- Apr 7th, 2022 7:54 pm
See Why Does HC Wainwright Maintain Neutral On Akebia Stock
- Apr 7th, 2022 6:38 pm
Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2022
- Apr 6th, 2022 12:30 pm
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 4th, 2022 8:30 pm
Akebia: Is There Any Value Left After the CRL? Analyst Weighs In
- Apr 1st, 2022 5:55 pm
Akebia stock tumbles after FDA rejects anemia drug
- Mar 31st, 2022 4:10 pm
FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia
- Mar 30th, 2022 7:34 pm
Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients
- Mar 30th, 2022 5:33 pm
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
- Mar 1st, 2022 10:35 pm
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights
- Mar 1st, 2022 9:01 pm
7 Speculative Penny Stocks Worth a Roll of the Dice
- Feb 25th, 2022 6:35 pm
Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch
- Feb 22nd, 2022 1:30 pm
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Discuss Recent Business Highlights
- Feb 9th, 2022 1:30 pm
Scroll